CTOs on the Move

Napp Technologies

www.napptech.com

 
Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.napptech.com
  • 401 Hackensack Ave
    Hackensack, NJ USA 07601
  • Phone: 201.843.4664

Executives

Name Title Contact Details

Similar Companies

Momentum for Health

CARF-accredited: Largest private nonprofit agency in Santa Clara County providing mental health services to over 3800 youth, adults and older adults annually.

VersaPharm Incorporated

VersaPharm Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).

Quality Dispensing Pharmacy

Quality Dispensing Pharmacy, Inc. is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.